Dr. Bilusic is a board-certified medical oncologist who treats genitourinary tumors (adrenal, kidney, prostate, bladder, and testis). His current research interests focus on tumor immunology and the development of novel immunotherapy approaches for prostate cancer and other genitourinary tumors using therapeutic cancer vaccines, antibodies, immune modulators or immune checkpoint inhibitors, not only as monotherapies but in combination with other therapies as part of an immuno-oncology programmatic effort.
Dr. Bilusic received his MD degree from the University of Zagreb School of Medicine in Croatia and completed his PhD training at the University of Split School of Medicine in Croatia. In addition, he completed a postdoctoral research fellowship in physiological genomics at the Medical College of Wisconsin's Human and Molecular Genetics Center in Milwaukee, WI. He successfully completed a clinical fellowship in medical oncology and hematology at the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI), in Bethesda, MD.
Dr. Bilusic served as an assistant professor (genitourinary medical oncology) at the Fox Chase Cancer Center/Temple Health from 2012 – 2016 and then joined the NCI Genitourinary Malignancy Branch in 2016 as an Associate Research Physician (equivalent to Associate Professor). During his time at the NCI, he also served as Associate Program Director, NIH Hematology Oncology Fellowship Program from July 2016 – July 2018, and then as Program Director from July 2018 – July 2021. In 2017, Dr. Bilusic received the National Institutes of Health Director's Award as a member of the NIH Hematology Oncology Fellowship Team for extraordinary resourcefulness and initiative. His passion for teaching and mentoring has earned multiple awards at NIH and NCI.
In July 2021, Dr. Bilusic joined Sylvester Comprehensive Cancer Center / University of Miami Health System as GU Medical Oncology Team Lead. He is board-certified in medical oncology, hematology, and internal medicine.